微新生物

Epitopea Ltd develops cancer immunotherapies intended to offer therapeutics targeting a novel class of tumour-specific antigen. The company's technology platform builds on our proprietary and innovative approach to identifying shared, aberrantly expressed tumour-specific antigens (aeTSA), known as CryptigenTM TSAs, curing cancer by targeting a new class of antigens that are broadly shared between patients with the same cancer indication.In May 2022, Novateur Ventures had participated in the $13.6M (£10.3M) seed investment raised by Epitopea Ltd.In April 2022, Epitopea had announced a $13.6M seed investment from Advent Life Sciences, CTI Life Sciences, Cambridge Innovation Capital and Fonds de solidarité FTQ

Alpha-9 Oncology 是一家处于临床阶段的放射性药物公司，致力于开发差异化和高度靶向性的放射性药物，有望显著改善癌症患者的治疗。Alpha-9 运用专有技术和深厚的基础专业知识，走在定制放射性药物工程的前沿，这些药物经过优化，可选择性地向肿瘤部位输送射线，同时最大限度地减少脱靶效应。Alpha-9 正在推进一个强大的新型放射性药物管线，该管线采用系统化的分子设计方法，具有向多个有效肿瘤靶点扩展的广泛潜力。

March Biosciences是一家临床阶段生物技术公司。该公司致力于治疗对现有免疫疗法无反应的挑战性癌症。其主要资产MB-105是一种以CD5为靶点的嵌合抗原受体T细胞（“CAR-T”）疗法，CD5是一个在正常和恶性T细胞（包括T细胞相关的白血病和淋巴瘤）中广泛表达的蛋白质。这限制了其作为癌症治疗靶点的用途，因为正常免疫系统功能所需的健康T细胞将与恶性T细胞一起被破坏。MB-105经过特别设计，既能保留健康的T细胞，又能保持对CD5阳性肿瘤细胞的杀伤力。